Basic Information
| RNALocate ID: | RLID:01001953 |
| RNA Symbol: | hsa-miR-200c-3p |
| Localization: | Nucleus |
RNA Information
| RNA Name: | hsa-miR-200c |
| RNA ID: | miRBase:MIMAT0000617 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 20864815 |
| Tissue/Cell Line: | Colon adenocarcinoma cells |
| Method: | Microarray |
| Description: | Reported gene targets of nuclear-associated microRNAs. Data are collected from Table 2. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01001951 | Mitochondrion | Cell line (HEK-293|HeLa) | 22984580 |
| RLID:01001952 | Nucleolus | Breast adenocarcinoma cells (MCF-7) | 24918059 |
| RLID:11002205 | Exosome | Urine | 26576778 |
| RLID:11002206 | Exosome | Breast cancer cell line (MCF-7) | 20976003 |
| RLID:11002207 | Exosome | Jurkat-derived T cell line (J77cl20) | 21505438 |
| RLID:11002208 | Exosome | Ascites fluid|Pleural effusion | 21601258 |
| RLID:11002209 | Exosome | Renal cancer cells | 21670082 |
| RLID:11002210 | Exosome | Brain tissue | 23382797 |
| RLID:11002211 | Exosome | Plasma | 23663360 |
| RLID:11002212 | Exosome | Colon cancer cell line (LIM1863) | 25330373 |
| RLID:11002213 | Extracellular vesicle | Plasma | 32498409 |
| RLID:11002214 | Microvesicle | Seminal plasma | 23539611 |
| RLID-D:11000105 | Exosome | Breast milk|Colon tissue|Seminal fluid|Tongue tissue | |
| RLID-D:11000392 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-200c-3p | Idiopathic pulmonary fibrosis | MNDR-E-MI-26335 |
| MNDR | hsa-miR-200c-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-26336 |
| MNDR | hsa-miR-200c-3p | Oral squamous cell carcinoma | MNDR-E-MI-26337 |
| MNDR | hsa-miR-200c-3p | Large cell neuroendocrine cancer | MNDR-E-MI-26338 |
| MNDR | hsa-miR-200c-3p | B cell lymphoma of malt type | MNDR-E-MI-26339 |
| MNDR | hsa-miR-200c-3p | High-grade serous ovarian carcinoma | MNDR-E-MI-26340 |
| MNDR | hsa-miR-200c-3p | Ovarian clear cell carcinoma | MNDR-E-MI-26341 |
| MNDR | hsa-miR-200c-3p | Uterine corpus endometrial carcinoma | MNDR-E-MI-26342 |
| MNDR | hsa-miR-200c-3p | Lymphoma | MNDR-E-MI-26343 |
| MNDR | hsa-miR-200c-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-26344 |
| MNDR | hsa-miR-200c-3p | Estrogen-receptor negative breast cancer | MNDR-E-MI-26345 |
| MNDR | hsa-miR-200c-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-26346 |
| MNDR | hsa-miR-200c-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-26347 |
| MNDR | hsa-miR-200c-3p | Her2-receptor positive breast cancer | MNDR-E-MI-26348 |
| MNDR | hsa-miR-200c-3p | Triple negative breast cancer | MNDR-E-MI-26349 |
| MNDR | hsa-miR-200c-3p | Breast cancer luminal | MNDR-E-MI-26350 |
| MNDR | hsa-miR-200c-3p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-26351 |
| MNDR | hsa-miR-200c-3p | B cell acute lymphoblastic leukemia | MNDR-E-MI-26352 |
| MNDR | hsa-miR-200c-3p | Prostate cancer | MNDR-E-MI-26353 |
| MNDR | hsa-miR-200c-3p | Prostate carcinoma | MNDR-E-MI-26354 |
| MNDR | hsa-miR-200c-3p | Gastric cancer | MNDR-E-MI-26355 |
| MNDR | hsa-miR-200c-3p | Alzheimer disease | MNDR-E-MI-26356 |
| MNDR | hsa-miR-200c-3p | Bladder cancer | MNDR-E-MI-26357 |
| MNDR | hsa-miR-200c-3p | Dysautonomia familial | MNDR-E-MI-26358 |
| MNDR | hsa-miR-200c-3p | Head and neck cancer | MNDR-E-MI-26359 |
| MNDR | hsa-miR-200c-3p | Leukemia | MNDR-E-MI-26360 |
| MNDR | hsa-miR-200c-3p | Leiomyoma | MNDR-E-MI-26361 |
| MNDR | hsa-miR-200c-3p | Huntington disease | MNDR-E-MI-26362 |
| MNDR | hsa-miR-200c-3p | Chorea | MNDR-E-MI-26363 |
| MNDR | hsa-miR-200c-3p | Cardiovascular disease | MNDR-E-MI-26364 |
| MNDR | hsa-miR-200c-3p | Lung cancer | MNDR-E-MI-26365 |
| MNDR | hsa-miR-200c-3p | Endometrial cancer | MNDR-E-MI-26366 |
| MNDR | hsa-miR-200c-3p | Down syndrome | MNDR-E-MI-26367 |
| MNDR | hsa-miR-200c-3p | Parkinson disease | MNDR-E-MI-26368 |
| MNDR | hsa-miR-200c-3p | Primary pulmonary hypertension | MNDR-E-MI-26369 |
| MNDR | hsa-miR-200c-3p | Breast cancer | MNDR-E-MI-26370 |
| MNDR | hsa-miR-200c-3p | Cancer | MNDR-E-MI-26371 |
| MNDR | hsa-miR-200c-3p | Thyroid cancer | MNDR-E-MI-26372 |
| MNDR | hsa-miR-200c-3p | Pituitary neoplasms | MNDR-E-MI-26373 |
| MNDR | hsa-miR-200c-3p | Pancreatic cancer | MNDR-E-MI-26374 |
| MNDR | hsa-miR-200c-3p | Hepatitis C | MNDR-E-MI-26375 |
| MNDR | hsa-miR-200c-3p | Melanoma | MNDR-E-MI-26376 |
| MNDR | hsa-miR-200c-3p | Williams syndrome | MNDR-E-MI-26377 |
| MNDR | hsa-miR-200c-3p | Nephroblastoma | MNDR-E-MI-26378 |
| MNDR | hsa-miR-200c-3p | Colon cancer | MNDR-E-MI-26379 |
| MNDR | hsa-miR-200c-3p | Ischemic attack transient | MNDR-E-MI-26380 |
| MNDR | hsa-miR-200c-3p | Colon adenocarcinoma | MNDR-E-MI-26381 |
| MNDR | hsa-miR-200c-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-26382 |
| MNDR | hsa-miR-200c-3p | Familial ovarian cancer | MNDR-E-MI-26383 |
| MNDR | hsa-miR-200c-3p | Acromegaly | MNDR-E-MI-26384 |
| MNDR | hsa-miR-200c-3p | Prostate adenocarcinoma | MNDR-E-MI-26385 |
| MNDR | hsa-miR-200c-3p | Kidney cancer | MNDR-E-MI-26386 |
| MNDR | hsa-miR-200c-3p | Endometrial adenocarcinoma | MNDR-E-MI-26387 |
| MNDR | hsa-miR-200c-3p | Endometrial carcinoma | MNDR-E-MI-26388 |
| MNDR | hsa-miR-200c-3p | Carcinoma ductal breast | MNDR-E-MI-26389 |
| MNDR | hsa-miR-200c-3p | Glioblastoma | MNDR-E-MI-26390 |
| MNDR | hsa-miR-200c-3p | Glioma | MNDR-E-MI-26391 |
| MNDR | hsa-miR-200c-3p | Epilepsy temporal lobe | MNDR-E-MI-26392 |
| MNDR | hsa-miR-200c-3p | Breast carcinoma | MNDR-E-MI-26393 |
| MNDR | hsa-miR-200c-3p | Liver neoplasms | MNDR-E-MI-26394 |
| MNDR | hsa-miR-200c-3p | Cervical adenocarcinoma | MNDR-E-MI-26395 |
| MNDR | hsa-miR-200c-3p | Ovarian adenocarcinoma | MNDR-E-MI-26396 |
| MNDR | hsa-miR-200c-3p | Gastric adenocarcinoma | MNDR-E-MI-26397 |
| MNDR | hsa-miR-200c-3p | Cervical squamous cell carcinoma | MNDR-E-MI-26398 |
| MNDR | hsa-miR-200c-3p | Pituitary adenoma | MNDR-E-MI-26399 |
| MNDR | hsa-miR-200c-3p | Lung squamous cell carcinoma | MNDR-E-MI-26400 |
| MNDR | hsa-miR-200c-3p | Non-small cell lung cancer | MNDR-E-MI-26401 |
| MNDR | hsa-miR-200c-3p | Lung adenocarcinoma | MNDR-E-MI-26402 |
| MNDR | hsa-miR-200c-3p | Thyroid carcinoma | MNDR-E-MI-26403 |
| MNDR | hsa-miR-200c-3p | Ovarian carcinoma | MNDR-E-MI-26404 |
| MNDR | hsa-miR-200c-3p | Bladder urothelial carcinoma | MNDR-E-MI-26405 |
| MNDR | hsa-miR-200c-3p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-26406 |
| MNDR | hsa-miR-200c-3p | Carcinoma renal cell | MNDR-E-MI-26407 |
| MNDR | hsa-miR-200c-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-26408 |
| MNDR | hsa-miR-200c-3p | Clear cell renal cell carcinoma | MNDR-E-MI-26409 |
| MNDR | hsa-miR-200c-3p | Large cell carcinoma | MNDR-E-MI-26410 |
| MNDR | hsa-miR-200c-3p | Biliary tract cancer | MNDR-E-MI-26411 |
| MNDR | hsa-miR-200c-3p | Intrahepatic cholangiocarcinoma | MNDR-E-MI-26412 |
| MNDR | hsa-miR-200c-3p | Cholangiocarcinoma | MNDR-E-MI-26413 |
| MNDR | hsa-miR-200c-3p | Esophageal cancer | MNDR-E-MI-26414 |
| MNDR | hsa-miR-200c-3p | Uterus leiomyosarcoma | MNDR-E-MI-26415 |
| MNDR | hsa-miR-200c-3p | Prolactinoma | MNDR-E-MI-26416 |
| MNDR | hsa-miR-200c-3p | Lung small cell carcinoma | MNDR-E-MI-26417 |
| MNDR | hsa-miR-200c-3p | Head and neck squamous cell carcinoma | MNDR-E-MI-26418 |
| MNDR | hsa-miR-200c-3p | Testicular germ cell cancer | MNDR-E-MI-26419 |
| MNDR | hsa-miR-200c-3p | T acute lymphoblastic leukemia | MNDR-E-MI-26420 |
| MNDR | hsa-miR-200c-3p | Acute t cell leukemia | MNDR-E-MI-26421 |
| MNDR | hsa-miR-200c-3p | Ovarian endometrial cancer | MNDR-E-MI-26422 |
| MNDR | hsa-miR-200c-3p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-26423 |
| MNDR | hsa-miR-200c-3p | Breast invasive carcinoma | MNDR-E-MI-26424 |
| MNDR | hsa-miR-200c-3p | Hepatocellular carcinoma | MNDR-E-MI-26425 |
| MNDR | hsa-miR-200c-3p | Familiar ovarian carcinoma | MNDR-E-MI-26426 |
| MNDR | hsa-miR-200c-3p | B-cell lymphoma | MNDR-E-MI-26427 |
| MNDR | hsa-miR-200c-3p | Retinoblastoma | MNDR-E-MI-26428 |
| MNDR | hsa-miR-200c-3p | Hodgkin lymphoma | MNDR-E-MI-26429 |
| MNDR | hsa-miR-200c-3p | Burkitt lymphoma | MNDR-E-MI-26430 |
| MNDR | hsa-miR-200c-3p | Crohn disease | MNDR-E-MI-26431 |
| MNDR | hsa-miR-200c-3p | Skin cutaneous melanoma | MNDR-E-MI-26432 |
| MNDR | hsa-miR-200c-3p | Skin melanoma | MNDR-E-MI-26433 |
| MNDR | hsa-miR-200c-3p | Systemic lupus erythematosus | MNDR-E-MI-26434 |
| MNDR | hsa-miR-200c-3p | Acute myelocytic leukemia | MNDR-E-MI-26435 |
| MNDR | hsa-miR-200c-3p | Colorectal cancer | MNDR-E-MI-26436 |
| MNDR | hsa-miR-200c-3p | Nasopharynx carcinoma | MNDR-E-MI-26437 |
| MNDR | hsa-miR-200c-3p | Multiple myeloma | MNDR-E-MI-26438 |
| MNDR | hsa-miR-200c-3p | Ovarian epithelial cancer | MNDR-E-MI-26439 |
| MNDR | hsa-miR-200c-3p | Epstein-barr virus infections | MNDR-E-MI-26440 |
| MNDR | hsa-miR-200c-3p | Non-alcoholic fatty liver disease | MNDR-E-MI-26441 |
| MNDR | hsa-miR-200c-3p | Breast cancer her3+ negative | MNDR-E-MI-26442 |
| MNDR | hsa-miR-200c-3p | Renal childhood neoplasms | MNDR-E-MI-26443 |
| MNDR | hsa-miR-200c-3p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-26444 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | ABCA2 | Homo sapiens | RR00022406 |
TOP